Leerink Swann Starts Synageva BioPharma (GEVA) at Market Perform
Tweet
Share
E-mailGet Alerts GEVA Hot Sheet
Price: $238.60 --0%
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Leerink Swann initiates coverage on Synageva BioPharma (NASDAQ: GEVA) with a Market Perform. PT $50.00.
Leerink analyst says, "Following a reverse merger last November and a public equity offering this January, we believe the company is well capitalized. We expect the shares to outperform as investors recognize that the proof of concept, favorable regulatory orphan drug path, magnitude of the potential opportunity and execution of this seasoned management team support a premium valuation."
"We believe SBC-102 addresses an estimated $600MM market opportunity in the US and Europe...GEVA also has a rapidly emerging preclinical protein therapeutics pipeline for orphan diseases, taking advantage of its proprietary protein expression platform."
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $36.00 yesterday.
Leerink analyst says, "Following a reverse merger last November and a public equity offering this January, we believe the company is well capitalized. We expect the shares to outperform as investors recognize that the proof of concept, favorable regulatory orphan drug path, magnitude of the potential opportunity and execution of this seasoned management team support a premium valuation."
"We believe SBC-102 addresses an estimated $600MM market opportunity in the US and Europe...GEVA also has a rapidly emerging preclinical protein therapeutics pipeline for orphan diseases, taking advantage of its proprietary protein expression platform."
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $36.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Starts Adani Green Energy (ADANIGR:IN) at Overweight
- Baird Starts Hubbell (HUBB) at Outperform
- UBS Starts Urban Company (URBANCO:IN) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
